Exelixis, Inc. (EXEL) has a MoatMap StockRank of 99/100 based on Quality (87/100), Value (47/100), and Momentum (62/100) factor scores. The current signal is STRONG BUY. Exelixis, Inc., a biopharmaceutical company focused on oncology, is a clear beneficiary of the 'Specialty Pharma & Biotech Growth' theme, featuring strong IP, high ROIC potential, an asset-light R&D model, and durable moats in its novel treatments.